Made in USA

Independently verifiedCertified

GLP-2-TZ · 30mg

Purity (HPLC)≥98%

LabVantage Analytical

Tested28 Jun 2026

Batch —·

Heavy metalsEndotoxinsMicrobialSolvents

View full COA

In stock

GLP-2-TZ

Name: GLP-2-TZ
Brand: AXOS
Availability: InStock

$139$4.63/mg

Dual GIP/GLP-1 receptor agonist — incretin axis metabolic research

Choose your size

Buy 1, Get 1 Free · auto-applied

Add 2+ items to cart to activate the discount

VISAAMEXPayPal

Secure, encrypted checkout

Independently verifiedCertified

GLP-2-TZ · 30mg

Purity (HPLC)≥98%

LabVantage Analytical

Tested28 Jun 2026

Batch —·

Heavy metalsEndotoxinsMicrobialSolvents

View full COA

Frequently bought together

Researchers usually add these to complete the protocol.

BAC Water · 3ml

Essential · Extras

GHK-CU · 50mg

Recovery

$39

Melanotan 2 · 10mg

Tanning

$49

Add all (3)$97

Certificate of analysis

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity
Raw chromatogram + mass confirmation attached
Signed off by the lab's Principal Chemist
Permanent archive — searchable by lot ID

View all lab reports

Reference reportView All Live Reports

Vantage Analytical

Independent analytical lab

Certificate of Analysis

RESULT · PASS

ProductGLP-2-TZ · 30mg

Lot / batch—

Reported28 Jun 2026

MethodHPLC-UV + LC-MS

AppearanceWhite lyophilized powder

ClientSolace Peptides

Analytical results

Identity (LC-MS)1419.5 DaPASS

Purity (HPLC-UV)≥98%PASS

Net content10.2 mgPASS

Endotoxin (LAL)< 0.05 EU/mgPASS

Heavy metals (ICP-MS)< 10 ppmPASS

Residual solventsBelow LOQPASS

HPLC Chromatogram

Purity ≥98%

Chemist verifiedDr. E. Hartley

Know your compound

What is GLP-2-TZ?

GLP-2-TZ is a synthetic dual-incretin receptor agonist that binds and activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor concurrently. Simultaneous engagement of both incretin arms distinguishes it structurally and pharmacologically from single-pathway GLP-1 receptor agonists studied in earlier preclinical and clinical programs.

Parallel activation of the GIP and GLP-1 receptor axes produces compound effects on glycaemic and metabolic markers that single-receptor compounds do not replicate in head-to-head study designs. Late-stage clinical research has documented statistically significant HbA1c reductions alongside improvements in lipid panel and blood pressure endpoints, establishing GLP-2-TZ as a reference comparator for dual-incretin mechanism research.

Statistically significant HbA1c reductions observed across late-stage clinical study programs
Favourable shifts in lipid profile and blood pressure markers reported in metabolic research models
Simultaneous GIP/GLP-1 receptor co-agonism — mechanistically distinct from single-pathway incretin reference compounds

Lot-specific COAEvery lot ships with an HPLC Certificate of Analysis and mass-spectrometry identity confirmation.

Institutional fulfilmentShipped to verified institutional addresses with full analytical documentation.

Lot-specific COA: Every lot ships with an HPLC Certificate of Analysis and mass-spectrometry identity confirmation.
Institutional fulfilment: Shipped to verified institutional addresses with full analytical documentation.

For research use only — not for human or veterinary use.

The research

What the research actually found

The published findings behind this compound — the headline numbers, in plain terms, each cited to source. Preclinical results are directional (animal / in-vitro) and shown for context, not as therapeutic claims.

Published research on the reference compound class. Provided for scientific context only — not a claim about the product supplied.

Blood sugarClinical

In late-stage randomised controlled trials in people with type 2 diabetes, statistically significant reductions in HbA1c — the standard long-term blood-sugar marker — were observed alongside dual GIP/GLP-1 receptor co-activation. Specific magnitudes were not confirmed from the supplied source material.

Journal of Diabetes and Its Complications, 2013 · Late-stage RCT

GLP-2-TZ (dual GIP/GLP-1)Placebo / reference

Schematic trajectory only — illustrates directional HbA1c trend; precise magnitudes not confirmed from source. Late-stage RCT, type 2 diabetes population.

Dual-receptor mechanismClinical

Simultaneous GIP and GLP-1 receptor co-agonism produced compound effects on metabolic markers in comparative research programs that were not replicated by single-receptor incretin reference compounds — suggesting a mechanistically distinct profile.

Dual GIP/GLP-1 (GLP-2-TZ)Compound effect

GLP-1-only referencePartial effect

Relative bar heights are schematic — directional only. No precise ratio confirmed from source. Comparative clinical research program.

Journal of Diabetes and Its Complications, 2013 · Comparative RCT program

Heart & metabolic riskClinical

Alongside glycaemic improvements, late-stage clinical metabolic research programs reported directional favourable shifts in both lipid panel markers and blood pressure endpoints — consistent with a broad cardiometabolic profile. Specific values were not confirmed from the supplied source material.

Lipid markersImproved (directional)

Blood pressureImproved (directional)

Reference / baselineBaseline

Bar fills are schematic and directional — precise deltas not confirmed from source. Late-stage clinical study, metabolic syndrome population.

Journal of Diabetes and Its Complications, 2013 · Late-stage RCT

GLP-1 Receptor AgonismGLP-1R activation

GIP Receptor AgonismGIPR activation

Incretin Axis Synergydual-receptor co-agonism

Mechanism

How GLP-2-TZ works

GLP-2-TZ is studied to exert its metabolic effects through three distinct receptor-level and downstream signalling routes associated with the incretin axis.

GLP-1 Receptor AgonismGLP-1R activation

Binding to the GLP-1 receptor in pancreatic beta cells is associated in preclinical and clinical models with glucose-dependent insulin secretion and suppression of glucagon release, contributing to the glycaemic effects observed in study endpoints.

GIP Receptor AgonismGIPR activation

Concurrent activation of the GIP receptor is studied for its additive effects on insulin secretion and potential contributions to lipid metabolism in adipose tissue — a pathway not engaged by single-GLP-1-receptor reference compounds.

Incretin Axis Synergydual-receptor co-agonism

Simultaneous engagement of both incretin receptors is hypothesised to produce non-additive downstream effects on metabolic signalling — including effects on lipid panels and cardiovascular markers — that neither receptor pathway produces alone in comparative study designs.

For research use only. Mechanisms described reflect published preclinical and clinical literature.

The process

How every batch is verified

01
Synthesized
Produced under controlled manufacturing with documented, repeatable processes.
02
HPLC purity
An independent lab reports the exact purity of every lot — a number, never a 'passes'.
03
Mass-spec identity
Molecular weight confirms the exact sequence is what the label says.
04
COA published
The certificate is posted to the open library, by lot, before the vial ships.

Verified researchers

Reviewed by people who test it themselves

Best sellers

Researchers reach for these

Best seller

5 Amino 1MQ

50mg

5.0

≥98% HPLC

$89

Best seller

BAC Water

10ml

5.0

$19

BPC-157

10mg

5.0

≥98% HPLC

$69

BPC-157 + TB-500

10mg + 10mg

5.0

≥98% HPLC

$119

CJC / Ipamorelin

5mg + 5mg

5.0

>98% HPLC

$99

CJC-1295 with DAC

5mg

5.0

≥98% HPLC

$79

FAQ

Frequently asked

Common questions about GLP-2-TZ

The COA guarantee

≥98% pure — or your money back.

Have any lot independently re-tested. If the results don't match the published certificate, we refund the order in full — no returns, no questions.

Order with cover

Third-party tested

An independent, accredited lab — no commercial interest in the result.

A COA on every lot

A lot-specific certificate ships with each vial, archived by batch.

Test it yourself → refund

Re-test any batch at any lab. A mismatch is a full refund.

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity

Raw chromatogram + mass confirmation attached

Signed off by the lab's Principal Chemist

Permanent archive — searchable by lot ID

View all lab reports

What is GLP-2-TZ?

Statistically significant HbA1c reductions observed across late-stage clinical study programs

Favourable shifts in lipid profile and blood pressure markers reported in metabolic research models

Simultaneous GIP/GLP-1 receptor co-agonism — mechanistically distinct from single-pathway incretin reference compounds

How GLP-2-TZ works

GLP-2-TZ is studied to exert its metabolic effects through three distinct receptor-level and downstream signalling routes associated with the incretin axis.

GLP-1 Receptor AgonismGLP-1R activation

GIP Receptor AgonismGIPR activation

Incretin Axis Synergydual-receptor co-agonism

For research use only. Mechanisms described reflect published preclinical and clinical literature.

Search

Search

Search

GLP-2-TZ

Every vial ships with its own report

What is GLP-2-TZ?

What the research actually found

How GLP-2-TZ works

GLP-1 Receptor AgonismGLP-1R activation

GIP Receptor AgonismGIPR activation

Incretin Axis Synergydual-receptor co-agonism

How every batch is verified

Researchers reach for these

Frequently asked

What is GLP-2-TZ and how does it differ from single-receptor GLP-1 agonists used as research references?

What does the clinical and preclinical research literature report about GLP-2-TZ's effects on metabolic markers?

Is GLP-2-TZ FDA-approved, and what is its regulatory status?

How is GLP-2-TZ used as a research tool in laboratory settings?

What are the molecular specifications of GLP-2-TZ relevant to assay design?

What are the recommended storage conditions for GLP-2-TZ?

≥98% pure — or your money back.

Search

Search

GLP-2-TZ

Every vial ships with its own report

What is GLP-2-TZ?

What the research actually found

How GLP-2-TZ works

GLP-1 Receptor AgonismGLP-1R activation

GIP Receptor AgonismGIPR activation

Incretin Axis Synergydual-receptor co-agonism

How every batch is verified

Researchers reach for these

Frequently asked

What is GLP-2-TZ and how does it differ from single-receptor GLP-1 agonists used as research references?

What does the clinical and preclinical research literature report about GLP-2-TZ's effects on metabolic markers?

Is GLP-2-TZ FDA-approved, and what is its regulatory status?

How is GLP-2-TZ used as a research tool in laboratory settings?

What are the molecular specifications of GLP-2-TZ relevant to assay design?

What are the recommended storage conditions for GLP-2-TZ?

≥98% pure — or your money back.